MYD88 and lymphoma: Both constructs were efficiently expressed on the T cell surface (Figure 6A) and showed specific and notable activation and cytolytic activity (Figure 6C) when targeting a stable lymphoma cell line (CD19+, CD80+, CD86+) derived from Prdm1.fl/Myd88/Bcl2 mice40 (Figure 6B).